Immunotherapy in cancer: Mechanisms and strategies to overcome resistance
Authors:
- Haigan YangHYHaigan Yang
- Zhehan YangZYZhehan Yang
- Xianzhe WangXWXianzhe Wang
- Harsh PatelHPHarsh Patel
- Zhuo-Xun WuZWZhuo-Xun Wu
- Charles R. AshbyCACharles R. Ashby
- Wei WangWWWei Wang
- Zhe-Sheng ChenZhe-Sheng Chen
- 13 July 2026
- journal article
- Published by Elsevier in Drug Resistance Updates
- Vol. 89
Abstract
No abstract availableFunding Information
- Guangzhou University of Chinese Medicine (GZY2025ZJ30)
- Guangzhou University of Chinese Medicine (09005647001)
This publication has 292 references indexed in Scilit:
- Disitamab vedotin, a HER2‐directed antibody‐drug conjugate, in patients with HER2‐overexpression and HER2‐low advanced breast cancer: a phase I/Ib studyCancer Communications, 2024
- Real‐world effectiveness and safety of RC48‐ADC alone or in combination with PD‐1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical studyCancer Medicine, 2023
- Manipulation of PD‐L1 Endosomal Trafficking Promotes Anticancer ImmunityAdvanced Science, 2022
- Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutionsCancer Communications, 2022
- KRAS ‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancerCancer Communications, 2022
- Thioester‐Assisted Sortase‐A‐Mediated LigationAngewandte Chemie, 2022
- Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast CancerJAMA Oncology, 2020
- Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expressionAmerican Journal of Hematology, 2017
- Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cellsEuropean Journal of Immunology, 2008
- Monoclonal AntibodiesJAMA, 1982